Frequently Asked Questions
About IVI
The International Vaccine Institute is an independent international organization originally established at the initiative of the United Nations Development Programme in 1997. IVI discovers, develops, and delivers safe, effective, and affordable vaccines—empowering vaccine equity, impact, and sustainability globally.
IVI accelerates vaccine research and development to protect people, especially vulnerable communities, from infectious diseases and enable healthy, productive lives.
With an innovative development model and public-private partnerships, IVI focuses on vaccines that are critically needed in resource-limited settings but often overlooked by major commercial developers.
IVI works end to end across vaccine discovery, development, delivery, epidemiology and surveillance, technology transfer, policy, and capacity strengthening.
Learn more about our approach.
As of 2025, IVI has a diverse, multidisciplinary workforce of more than 300 people representing 36 nationalities, including biomedical scientists, infectious disease experts, medical doctors and nurses, health economists, vaccine advocates, educators, communicators, and more.
Meet our Leadership Team. Explore our career opportunities.
IVI is headquartered in Seoul, Republic of Korea, with programs and collaborations across more than 40 countries on six continents. We have a Europe Regional Office in Stockholm, Sweden; an Africa Regional Office in Kigali, Rwanda; the Austria Country Office in Vienna; and the Kenya Country and AVEC Africa Project Office in Nairobi.
IVI additionally co-founded the Hong Kong Jockey Club Global Health Institute in Hong Kong SAR, China, and has Collaborating Centers in Bhutan, Burkina Faso, Ethiopia, Ghana, Madagascar, and Nepal.
IVI works closely with governments, vaccine developers and manufacturers, philanthropies and foundations, international organizations and public-private partnerships, policymakers, universities, hospitals, and businesses to make safe, effective, and affordable vaccines available to the people who need them.
Six governments provide state funding for IVI as of 2025: the Republic of Korea, Sweden, India, Finland, Austria, and Thailand. Much of IVI’s work comes from research grants written by scientists at IVI and their collaborators. These grants come from government, philanthropic, multilateral, academic, and industry partners, including the Gates Foundation, Wellcome, and the Coalition for Epidemic Preparedness Innovations, among others.
IVI does not directly fund grants for research and development to other organizations or individuals. However, IVI often awards subcontracts to external collaborators for select projects.
- Antigen discovery, preclinical development, new vaccine development, and development and standardization of laboratory assays in support of vaccine research and development, with expertise in molecular, clinical, and translational immunology
- Vaccine process and analytical development
- Animal studies and biosafety
- Technology transfer and manufacturing support
- Public health, including epidemiology, interventions and implementation research, policy and health economics, biostatistics, and data management
- Clinical development and operations across phase I–IV clinical trials
- Regulatory affairs and WHO prequalification support
- Vaccination campaigns and vaccine effectiveness studies
- Antimicrobial resistance surveillance and research
- Quality management
- Project and coalition management
- Global affairs, government and public relations, communications, and advocacy
- Training and capacity strengthening
IVI is uniquely present at every step of the vaccine value chain. From public health research at field sites around the world to preclinical discovery and development in the lab, clinical trials and vaccine effectiveness studies, technology transfers and registration with manufacturers, and vaccination campaigns and policy engagement, IVI bridges discovery, development, and delivery to turn vaccine science into public health impact.
IVI is a treaty-based international organization established through the Agreement on the Establishment of the International Vaccine Institute, which was opened for signature in 1996 and deposited with the United Nations. As of September 2026, 44 countries and the World Health Organization are members of IVI.
Parties to the Establishment Agreement participate in the Global Council. States Parties that provide voluntary financial contributions to IVI are eligible for representation on the Board of Trustees, while two additional Board seats are reserved for non-funding States Parties.
Learn more about IVI’s members.
IVI develops vaccines but does not operate as a commercial vaccine manufacturer. Instead, we discover new vaccine candidates, improve existing vaccines, establish production processes, conduct and support clinical development, and transfer vaccine technologies to manufacturing partners.
An oral cholera vaccine and Vi-DT typhoid conjugate vaccine were developed at IVI laboratories. IVI is also advancing vaccines and vaccine technologies against diseases including Klebsiella pneumoniae, invasive non-typhoidal Salmonella, Shigella, group A Streptococcus, cholera, and emerging infectious diseases.
In addition to its own vaccines, IVI assists vaccine developers around the world with preclinical and clinical development, assays, regulatory strategy, manufacturing support, and technology transfer.
IVI’s current portfolio includes research and vaccine development across a broad range of infectious diseases that disproportionately affect low- and middle-income countries or pose epidemic and pandemic threats. These include cholera, typhoid fever, chikungunya, shigellosis, salmonellosis, schistosomiasis, hepatitis E, HPV-related diseases, group A Streptococcus-related diseases, COVID-19, Klebsiella pneumoniae, Rift Valley fever, severe fever with thrombocytopenia syndrome, rotavirus, tuberculosis, MERS, and other emerging threats.
IVI also conducts extensive antimicrobial resistance research and surveillance, including work to measure how vaccination can reduce antimicrobial use and resistance.
Learn more about IVI’s areas of research.
About vaccines
Vaccines train the body’s immune system to recognize and fight pathogens like viruses and bacteria.
When you receive a vaccine, you introduce your body to a piece of the germ or a version of a germ that won’t harm you but will trigger an immune (or defensive) response. So, if you come across the “real thing” in the future, your body will quickly remember how to protect against the potentially dangerous germ. This is called immunological memory.
Vaccination saves lives. Immunization has saved 154 million lives over the past half century and millions more from illness and disability, according to the WHO. Vaccines have eliminated or eradicated dangerous infectious diseases from significant regions of the global map, protect against cancer, reduce the spread of antimicrobial resistance, and help mitigate the health ramifications of climate change.
Beyond health benefits, vaccination enables children to perform better in school and adults to continue working without the burden of preventable disease. Vaccination also reduces poverty and increases equality and access to opportunities.
Learn more about the value of vaccines.
Vaccines have two major types of ingredients: antigens, which create an immune or “defensive” response in your body by producing protective antibodies, and adjuvants, which help boost that immune response. Other ingredients may be preservatives and residual antibiotics to prevent contamination, and stabilizers to keep vaccines potent after manufacturing.
Vaccine development begins in the lab with scientists creating a vaccine candidate. There are six main types of vaccines: live attenuated (which contain whole bacteria or viruses, though weakened), inactivated (with killed bacteria or viruses, or small parts of them), subunit (which contain only pieces of the bacteria or virus), conjugate (which connect pieces from the bacteria’s coating to antigens), toxoid (which only contain the part of the pathogen that causes disease), and viral vector-based vaccines (which use a harmless virus to deliver genetic code for antigen).
The new vaccine then enters pre-clinical research which includes testing in animals to see if the right kind of immune responses are generated. Then, testing in humans proceeds in three phases:
- Phase I primarily tests for safety while also looking for the antibody responses. This earliest stage of testing in humans recruits a small number of healthy adults.
- Phase II is larger and focuses on the amount of antibody responses. These trials often run for one year or longer, involving hundreds of volunteers, followed by safety analysis.
- Phase III proves that a vaccine is safe and protects against disease. This final stage of clinical testing often involves thousands of people with a portion receiving a placebo.
Following clinical development, results are submitted for extensive review and ultimately approval by a regulatory authority (e.g., MFDS in the Republic of Korea), followed by WHO prequalification.
On a traditional timeline, it takes on average 5-10 years to take a vaccine from the laboratory to a vaccination program. Every stage from discovery through regulatory review can take at least two years, sometimes up to five. Once a vaccine proves to be safe and effective, building the manufacturing capacity to make enough vaccine also takes time.
Unlike antibiotics, viruses and bacteria very infrequently become resistant to established vaccines. In the case of influenza (the flu), vaccine strains appear to change yearly through mutation or with new strains around the world and vaccine has to be adapted to the circulating strains every year.
However, most other vaccines do not experience major problems with resistance. The graphic below shows the time to detection of resistance to antimicrobials (in red) and to vaccines (in green). Source: Front. Immunol.

Vaccines are a sustainable solution to disease prevention and are sometimes used for large outbreaks of multidrug resistant bacteria, like Salmonella Typhi.
On the other hand, increasing resistance to antibiotics has become a major threat to global health, exacerbated by overuse and misuse of antibiotics. Vaccination is an important tool against antimicrobial resistance by preventing infection in the first place and reducing (mis)use of antibiotics.

